1190380-38-1

Basic information

• Product Name: 5-Amino-2,3-dihydro-2-met...
• Synonyms: 5-Amino-2,3-dihydro-2-met...;5-aMino-2-Methylisoindolin-1-one;5-amino-2-methyl-2,3-dihydro-1H-isoindol-1-one
• CAS NO: 1190380-38-1
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.1885
• Mol File: 1190380-38-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Amino-2,3-dihydro-2-met...(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-2,3-dihydro-2-met...(1190380-38-1)
• EPA Substance Registry System: 5-Amino-2,3-dihydro-2-met...(1190380-38-1)

Safety Data

• Hazardous Substances Data: 1190380-38-1(Hazardous Substances Data)

Usage

General Description

5-Amino-2,3-dihydro-2-methyl-1-phenyl-1H-pyrazolo[3,4-b]quinoline-1,4-dione, commonly known as methazolastone, is a synthetic chemical compound that belongs to the pyrazoloquinoline family. It possesses anti-tumor properties and is primarily used in the treatment of Hodgkin's disease (a type of lymphoma), non-Hodgkin's lymphoma, malignant melanoma and other types of cancer of the lung, breast, and kidney. This chemical operates by inhibiting the DNA synthesis of cancerous cells, thereby preventing their rapid proliferation. Notably, its administration can have side effects including nausea, vomiting, and diarrhea, which should be managed under medical observation.

Upstream product

• 1190380-36-9 2-methyl-5-nitroisoindolin-1-one 
• 133446-99-8 2-bromomethyl-4-nitro-benzoic acid methyl ester 
• 62621-09-4 methyl 2-methyl-4-nitrobenzoate 
• 1975-51-5 2-methyl-4-nitrobenzoic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3–fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.

Diarylurea PI3Kalpha/mTOR double-target inhibitor and pharmaceutical composition, and application of inhibitor and pharmaceutical composition

The invention discloses a diarylurea PI3Kalpha/mTOR double-target inhibitor as well as a pharmaceutical composition, and application of the diarylurea PI3K alpha/mTOR double-target inhibitor and the pharmaceutical composition. The diarylurea PI3Kalpha/mTOR double-target inhibitor comprises a substituted triazine compound with a general formula (I) described in the specification, and a stereoisomer, a hydrate or a pharmaceutically acceptable salt thereof. The diarylurea PI3Kalpha/mTOR double-target inhibitor provided by the invention and the pharmaceutical composition containing the diarylurea PI3K alpha/mTOR double-target inhibitor can be used for inhibiting PI3Kalpha/mTOR double kinase and proliferative diseases caused by the PI3Kalpha/mTOR double kinase, and an inhibitor with better effectiveness and selectivity can be provided for treatment of the PI3Kalpha/mTOR double-kinase-induced proliferative diseases.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. Such compounds have general formula I or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, W, Ry, R3 and R4 are as defined herein.